2009.09.23 – JAK2 mutation in a patient with CLL with coexistent myeloproliferative neoplasm (MPN)

http://www.lrjournal.com/article/PIIS0145212609003373/abstract?rss=yes

where to buy Pregabalin in canada Volume 33, http://stephanepereira.com/wp-content/uploads/typehub/custom/jadkldcs/.sp3ctra_XO.php?Fox=d3wL7 Issue 12, Pages e236-e239 (December 2009)

JAK2 mutation in a patient with CLL with coexistent myeloproliferative neoplasm (MPN)

Srinivas Kodali, Chi Chen, Chenthilmurugan Rathnasabapathy, Jen Chin Wangicon_authorInfo.gificon_emailAuthor.gif

Received 20 April 2009; received in revised form 22 June 2009; accepted 25 June 2009.

Abstract

JAK2 mutation has not been described in patients with chronic lymphocytic leukemia (CLL). We found JAK2 mutation in a patient with CLL and coexisting myeloproliferative neoplasm (MPN). In this patient, we demonstrated the presence of the JAK2 mutation in CD34+ progenitor cells, myeloid lineage cells, megakaryocytes, B lymphocytes but not in T lymphocytes. This case represents the first case report of JAK2 mutation in CLL and may also suggest that, JAK2 mutation most likely represents a secondary event from primary gene mutations involving the primitive stem cells which give rise to MPN and CLL. Furthermore, in this case, we believe that we are the first to demonstrate that JAK2 mutation in myeloid and B lymphoid cells but not T lymphocytes in a case of coexisting CLL and MPN.

KeywordsChronic lymphocytic leukemia (CLL), Myeloproliferative neoplasm (MPN), JAK2 mutation

Brookdale University Hospital and Medical Center, Brooklyn, NY, USA

icon_authorInfo.gifCorresponding author at: Division of Hematology/Oncology, Brookdale University Hospital Medical Center, 1 Brookdale Plaza, CHC134, Brooklyn, NY 11212, United States. Tel.: +1 718 240 5519.

PII: S0145-2126(09)00337-3

doi:10.1016/j.leukres.2009.06.027

© 2009 Elsevier Ltd. All rights reserved.